跳至主要内容
临床试验/DRKS00031024
DRKS00031024招募中Unknown

Optimization of polypharmacy in geriatric oncology - OPTIMA

Deutsches Krebsforschungszentrum0 个研究点目标入组 514 人开始时间: 2023年2月13日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
514

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
65 Years 至 one(—)
性别
All

入选标准

  • Diagnosis or recurrence requiring treatment of one of 22 frequent cancers (see chapter „Health condition for complete list) in last 5 years
  • Exposure to polypharmacy, defined as = 5 chronically, concurrently used active substances
  • At least 3 weeks of in-patient rehabilitation in a cooperating clinic are planned
  • Sufficient capabilities for informed consent

排除标准

  • No written informed consent to participate
  • No sufficient mental and physical capabilities to fill self-administered questionnaires.
  • No sufficient knowledge of the German language.
  • Missing information needed to conduct the medication review with the FORTA list
  • No medication related problem at baseline (FORTA score = 0).
  • Missing baseline information needed for the primary endpoint (global quality of life).

研究者

发起方
Deutsches Krebsforschungszentrum

相似试验